An EORTC phase I study of capecitabine (Xeloda(R)) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer

Author: Bonnefoi H.   Biganzoli L.   Mauriac L.   Cufer T.   Schaefer P.   Atalay G.   Piccart M.  

Publisher: Elsevier

ISSN: 0959-8049

Source: European Journal of Cancer, Vol.39, Iss.9, 2003-06, pp. : 1277-1283

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content